Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Liabilities: 2016-2025

Historic Total Liabilities for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $417.8 million.

  • Tg Therapeutics' Total Liabilities rose 6.08% to $417.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $417.8 million, marking a year-over-year increase of 6.08%. This contributed to the annual value of $355.3 million for FY2024, which is 110.15% up from last year.
  • Per Tg Therapeutics' latest filing, its Total Liabilities stood at $417.8 million for Q3 2025, which was down 1.97% from $426.2 million recorded in Q2 2025.
  • Tg Therapeutics' Total Liabilities' 5-year high stood at $426.2 million during Q2 2025, with a 5-year trough of $98.2 million in Q3 2021.
  • Over the past 3 years, Tg Therapeutics' median Total Liabilities value was $223.6 million (recorded in 2024), while the average stood at $285.0 million.
  • In the last 5 years, Tg Therapeutics' Total Liabilities declined by 5.26% in 2022 and then spiked by 136.84% in 2024.
  • Tg Therapeutics' Total Liabilities (Quarterly) stood at $142.5 million in 2021, then fell by 5.26% to $135.0 million in 2022, then grew by 25.26% to $169.1 million in 2023, then skyrocketed by 110.15% to $355.3 million in 2024, then rose by 6.08% to $417.8 million in 2025.
  • Its last three reported values are $417.8 million in Q3 2025, $426.2 million for Q2 2025, and $419.4 million during Q1 2025.